Oramed Reaches 50% Enrollment in Phase 3 Oral Insulin Study

First and Largest of two concurrent Phase 3 trials on track to complete randomization by Q4 2021 NEW YORK, June 8, 2021 /PRNewswire/ — Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has enrolled and randomized over 50% […]

Join our mailing list

Skip to content